Profile
Mediphage Bioceuticals, a preclinical-stage biotechnology company, is developing a next-generation non-viral gene therapy platform based on its proprietary mini string DNA (msDNA) technology. A Toronto-based company, founded in 2016, Mediphage uses a proprietary manufacturing process to develop safe, durable and redosable gene delivery vectors. msDNA is designed to overcome critical challenges facing viral gene therapies and leverage advancements in the delivery of nucleic acids.
Website
www.mediphage.bioContact
-
Alvaro Amorrortu, President and Chief Executive OfficerTel: +1 647 447-7449Email: alvaro.amorrotu@mediphage.ca
Event details
Date: September 13 - 15, 2021
Event contact
Patricia Cosgrove
Area Director
USA: Life Sciences
Tel: +1 647-293-6306
Email: patricia.cosgrove@ontario.ca
Participants
6 in total
-
Artenga’s microbubble drug conjugates (MDC) and focused ultrasound (FUS) are key… -
KA Imaging has created color x-ray, which allows for early and more accurate diagnostics with higher radiology… -
Mediphage Bioceuticals, a preclinical-stage biotechnology company, is developing a next-generation non-viral gene…
-
Nanology Labs, a University of Toronto spin-off company, has developed a novel drug delivery platform technology… -
Nucro-Technics is a full-service Contract Support Organization that specializes in the conduct of both GLP… -
PocketMD is a 24/7 healthcare marketplace that connects patients with doctors and allied health professionals…